tirzepatide loss of exclusivity Generic Zepbound Explained: The Patent Landscape Tirzepatide for Medical Weight Loss

The decision to prescribe these medications considers multiple factors, including BMI, presence of insulin resistance or prediabetes, previous weight loss attempts, and overall metabolic health

During a week-long gap, many patients experience a significant rebound in cravings, increased portion sizes at meals, and a return of pre-treatment eating patterns

It belongs to a novel class of agents known as triple agonists, meaning it is designed to target three distinct hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor

When performing an intention-to-treat analysis, the HR for MOF was found to be 0.89 [0.781.02] with GLP-1 RAs compared to DPP-4is, although this became significant in the fully adjusted model (HR 0.85 [0.74 0.98])